GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development work
GH Research reported a widened net loss of USD 34.11 million for the first half of 2026, primarily due to increased operating costs. Research and development expenses significantly rose to USD 24.78 million, driven by clinical and technical development work on GH001. Despite the …